Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 117(7): 1017-1025, 2017 Sep 26.
Article in English | MEDLINE | ID: mdl-28772284

ABSTRACT

BACKGROUND: The direct comparison of CA19.9, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis of solid pancreatic tumours (SPTs). METHODS: We included 68 patients with a SPT referred for EUS-FNA. CTCs were analysed using size-based platform and ctDNA using digital PCR. The sensitivity, specificity, negative and positive predictive values were evaluated for each marker and their combination. RESULTS: SPTs corresponded to 58 malignant tumours (52 pancreatic adenocarcinoma (PA) and 6 others) and 10 benign lesions. The sensitivity and specificity for PA diagnosis were 73% and 88% for EUS-FNA, 67% and 80% for CTC, 65% and 75% for ctDNA and 79% and 93% for CA19.9, respectively. The positivity of at least 2 markers was associated with a sensitivity and specificity of 78% and 91%, respectively. CtDNA was the only marker associated with overall survival (median 5.2 months for ctDNA+ vs 11.0 months for ctDNA-, P=0.01). CONCLUSIONS: CA19.9 alone and in combination with ctDNA and/or CTC analysis may represent an efficient method for diagnosing PA in patients with SPTs. Further studies including a larger cohort of patients with both malignant and benign lesions will be necessary to confirm these promising results.


Subject(s)
Adenocarcinoma/blood , Adenocarcinoma/diagnosis , CA-19-9 Antigen/blood , DNA, Neoplasm/blood , Neoplastic Cells, Circulating , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/diagnosis , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Endoscopic Ultrasound-Guided Fine Needle Aspiration , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Predictive Value of Tests , Proto-Oncogene Proteins p21(ras)/genetics , Survival Rate , Young Adult
2.
Hum Genet ; 124(5): 473-8, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18932004

ABSTRACT

Biallelic and heterozygous mutations of the BUB1B gene have been reported in mosaic variegated aneuploidy (MVA), a rare disorder characterized by constitutional mosaic aneuploidies associated to severe intrauterine growth retardation, microcephaly and, in most cases, to premature chromatid separation (PCS), highlighting the key role of human BUBR1 in chromosome segregation. To study the consequences of gradual reduction of the BUBR1 protein levels, inhibition of BUB1B expression in model cells was induced using short hairpin RNAs (shRNAs). We obtained stable shRNA-transduced HeLa cells displaying a gradient of residual BUBR1 protein (8.5, 10, 14, 58, and 77%), mimicking the situation of patients' cells harboring one or two BUB1B mutations. Induction of PCS was detected in all transduced cells and its level was correlated to the decrease of BUBR1. Aneuploidy was clearly detected in cells with residual BUBR1 below 50%. Our data demonstrate that the function of the human BUBR1 protein in the spindle checkpoint is remarkably dosage-dependent and that the biological consequences of BUB1B expression reduction on premature chromatid separation and aneuploidy depend on the residual amount of BUBR1. This provides a biological explanation for the mode of inheritance of PCS, which is dominant, and of MVA, which can be recessive in some families and result from the combination of a null allele associated to a common hypomorphic allele in others.


Subject(s)
Aneuploidy , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Sister Chromatid Exchange/genetics , Sister Chromatid Exchange/physiology , Alleles , Base Sequence , Cell Cycle , Cell Line , Gene Dosage , HeLa Cells , Humans , Molecular Sequence Data , Mosaicism , Mutation , Protein Serine-Threonine Kinases/antagonists & inhibitors , RNA/genetics , RNA Interference , Transduction, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...